This combination is indicated for:

• As an adjunct to specific therapy in osteoporosis
• Increased requirements of Calcium, Vitamin C, and Vitamin D such as during pregnancy, lactation, rapid growth (childhood and adolescence), and in elderly individuals
• Management of osteomalacia
• Prevention and treatment of calcium and Vitamin D deficiency, especially in housebound or hospitalized patients
• As supportive therapy in common cold and influenza
• Postmenopausal conditions
• Premenstrual symptoms
• During febrile conditions (high body temperature)
• As an alkalizing agent in conditions of systemic acidosis

Each effervescent tablet contains:

• Calcium Lactate Gluconate 1000 mg
• Calcium Carbonate BP 327 mg
• Ascorbic Acid (Vitamin C) BP 500 mg
• Vitamin D3 400 IU (as Cholecalciferol BP)

Calcium gluconate provides a bioavailable source of calcium, which is essential for normal nerve conduction, muscle function, and cardiac activity. It helps maintain calcium balance and prevent bone loss.

Calcium carbonate supplies additional calcium and contributes to maintaining adequate calcium levels in the body. It plays a key role in supporting bone structure and overall physiological functions.

Vitamin C is an essential nutrient that the body cannot synthesize. It acts as a potent antioxidant, supports immune function, and plays an important role in the body’s response to stress and protection against infections.

Vitamin D3 is crucial for bone health as it enhances calcium absorption from the gastrointestinal tract and promotes bone formation. It works synergistically with calcium to improve bone strength and helps in preventing osteoporosis and fractures.

Adolescents & Adults: 1 effervescent tablet per day.
Children: ½ effervescent tablet per day.
Infants: As prescribed by the physician.

Dissolve one tablet in a glass of water.

Patients taking thiazide diuretics should be monitored for hypercalcemia, as these drugs reduce urinary calcium excretion. Hypercalcemia should be avoided in patients receiving digitalis therapy. Certain foods (e.g., those containing oxalic acid, phosphate, or phytic acid) may decrease calcium absorption. Concomitant use of phenytoin or barbiturates may reduce the effectiveness of Vitamin D due to increased metabolic breakdown. The effects of digitalis and other cardiac glycosides may be enhanced when used together with calcium and Vitamin D. Calcium salts may interfere with the absorption of thyroxine, bisphosphonates, sodium fluoride, quinolone or tetracycline antibiotics, and iron. A minimum interval of 4 hours should be maintained between calcium and these medications.

This preparation is contraindicated in patients with hypercalcemia due to conditions such as myeloma, bone metastases, or other malignant bone diseases, as well as sarcoidosis, primary hyperparathyroidism, and Vitamin D overdose. It is also contraindicated in severe renal failure and in patients with hypersensitivity to any of its components.

Calcium supplementation is generally well tolerated but may occasionally cause mild gastrointestinal disturbances such as constipation, flatulence, nausea, abdominal discomfort, and diarrhea. Long-term use of Vitamin D may rarely cause skin rash. Hypercalciuria and, in rare cases, hypercalcemia have been reported with prolonged high-dose Vitamin D therapy.

Use during pregnancy and lactation should be under medical supervision. Requirements for calcium and Vitamin D increase during these periods; however, total intake should consider other dietary and supplemental sources. Excessive Vitamin D intake has shown teratogenic effects in animal studies. Vitamin D and its metabolites are excreted into breast milk.

Patients with mild to moderate renal impairment or mild hypercalciuria should be monitored carefully. Regular evaluation of plasma calcium and urinary calcium excretion is recommended. In patients with a history of kidney stones, urinary calcium should be assessed to exclude hypercalciuria. During long-term therapy, serum calcium levels and renal function should be monitored. Treatment should be reduced or temporarily discontinued if urinary calcium exceeds 7.5 mmol/24 hours. Intake from other calcium and Vitamin D sources should also be considered.

The most serious consequence of acute or chronic overdose is hypercalcemia due to Vitamin D toxicity. Symptoms may include nausea, vomiting, excessive urination, and constipation. Chronic overdose can lead to vascular and organ calcification. Management involves discontinuation of calcium and Vitamin D intake and adequate rehydration.

Specific mineral & vitamin combined preparations

Store in a cool and dry place, protected from light and moisture. Keep out of reach of children. Keep the container tightly closed.